Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MX006 in Advanced Solid Tumors Expressing B7-H3
NCT07807241Phase 1Recruiting
- Sponsor
- Myricx Bio
- Start
- Jul 2026
- Primary completion
- Jul 2030
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of MX006 in solid tumor (2 arms), sponsored by Myricx Bio. Primary endpoints: Frequency and severity of adverse events and serious adverse events at 90 days, Clinically significant change from baseline safety laboratory values at 30 days and 4 more. Started Jul 2026; status: recruiting.
02
Drugs
MX006
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07807241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07807241.